Age-related monoclonal gammapathies: clinical lessons from the aging C57BL mouse.
In this article the long-held notion that benign monoclonal gammapathy (BMG) is a premalignant stage in the development of multiple myeloma (MM) is attacked. Jiri Radl argues that clinical and experimental observations indicate that they are separate entities which may be distinguished in the laboratory and which should be managed in radically different ways.
TNO Institute for Experimental Gerontology, Rijswijk, The Netherlands.
J
J
Radl
D000375:Aging / Q000473:pathology*; D000818:Animals; D001402:B-Lymphocytes / Q000473:pathology; D002470:Cell Survival; D002999:Clone Cells / Q000473:pathology; D006801:Humans; D006942:Hypergammaglobulinemia / Q000473:pathology*; D007153:Immunologic Deficiency Syndromes / Q000150:complications / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL / Q000254:growth & development*; D008954:Models, Biological; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000145:classification / Q000473:pathology*; D009101:Multiple Myeloma / Q000209:etiology; D011230:Precancerous Conditions